Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 60 Published: March 31, 2022 Report Code: GMDGDHC22086IDB

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in  the  stools,  diarrhea  or  constipation,  weight  loss  due  to  unknown  reason  and  abdominal  pain.  Treatment  includes surgery and medications (NSAIDs).

The Familial Adenomatous Polyposis – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects.

Key Targets in the Familial Adenomatous Polyposis Pipeline Drugs Market

The key targets in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others.

Familial Adenomatous Polyposis Drugs Market, by Targets

Familial Adenomatous Polyposis Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Familial Adenomatous Polyposis Pipeline Drugs Market

The key mechanisms of action in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist.

Familial Adenomatous Polyposis Pipeline Drugs Market, by MoA

Familial Adenomatous Polyposis Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Familial Adenomatous Polyposis Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Familial Adenomatous Polyposis pipeline drugs market are Subcutaneous, Intravenous, Oral, and Intradermal.

Familial Adenomatous Polyposis Pipeline Drugs Market Analysis, by RoA

Familial Adenomatous Polyposis Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Familial Adenomatous Polyposis Pipeline Drugs Market

The key molecule types in the Familial Adenomatous Polyposis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine among others.

Familial Adenomatous Polyposis Pipeline Drugs Market, by Molecule Type

Familial Adenomatous Polyposis Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Familial Adenomatous Polyposis Pipeline Drugs Market

The major companies in the Familial Adenomatous Polyposis pipeline drugs market are Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix Bio Pvt Ltd, DNAlite  Therapeutics  Inc, and Eloxx Pharmaceuticals Inc among others.

Familial Adenomatous Polyposis Pipeline Drugs Market, by Major Companies

Familial Adenomatous Polyposis Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Familial Adenomatous Polyposis Pipeline Drugs Market Overview

Key Targets Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others.
Key Mechanisms of action Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist

 

Key Routes of Administration Subcutaneous, Intravenous, Oral, and Intradermal
Key molecule types Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine
Major companies Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix  Bio  Pvt  Ltd, DNAlite  Therapeutics  Inc, and Eloxx Pharmaceuticals Inc among others.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Familial Adenomatous Polyposis

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • ADT Pharmaceuticals Inc

    Cancer Prevention Pharmaceuticals Inc

    Cellix Bio Pvt Ltd

    DNAlite Therapeutics Inc

    Eloxx Pharmaceuticals Inc

    Emtora Biosciences

    FunPep Co Ltd

    Jiangsu Hengrui Medicine Co Ltd

    Johnson & Johnson

    KD Pharma Group SA

    Recursion Pharmaceuticals Inc

    SanaRx Biotherapeutics Inc

    Stemsynergy Therapeutics Inc

    Sumitomo Dainippon Pharma Co Ltd

    TherapyX Inc

    Thetis Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Familial Adenomatous Polyposis – Overview

Familial Adenomatous Polyposis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Familial Adenomatous Polyposis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Familial Adenomatous Polyposis – Companies Involved in Therapeutics Development

ADT Pharmaceuticals Inc

Cancer Prevention Pharmaceuticals Inc

Cellix Bio Pvt Ltd

DNAlite Therapeutics Inc

Eloxx Pharmaceuticals Inc

Emtora Biosciences

FunPep Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

KD Pharma Group SA

Recursion Pharmaceuticals Inc

SanaRx Biotherapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

TherapyX Inc

Thetis Pharmaceuticals LLC

Familial Adenomatous Polyposis – Drug Profiles

(eflornithine hydrochloride + sulindac) – Drug Profile

Product Description

Mechanism Of Action

History of Events

CLXONC-575 – Drug Profile

Product Description

Mechanism Of Action

FAPXIL SR – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Familial Adenomatous Polyposis – Drug Profile

Product Description

Mechanism Of Action

guselkumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

icosapent ethyl – Drug Profile

Product Description

Mechanism Of Action

History of Events

interleukin-10 SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

lorpucitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

magnesium lysinate bis eicosapentaenoate – Drug Profile

Product Description

Mechanism Of Action

History of Events

ombipepimut-s – Drug Profile

Product Description

Mechanism Of Action

History of Events

pyrvinium pamoate – Drug Profile

Product Description

Mechanism Of Action

History of Events

REC-4881 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-201 – Drug Profile

Product Description

Mechanism Of Action

SHR-1020 – Drug Profile

Product Description

Mechanism Of Action

sirolimus – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Familial Adenomatous Polyposis – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PDE10 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic peptide for Familial Adenomatous Polyposis – Drug Profile

Product Description

Mechanism Of Action

History of Events

ZKN-013 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Familial Adenomatous Polyposis – Dormant Projects

Familial Adenomatous Polyposis – Discontinued Products

Familial Adenomatous Polyposis – Product Development Milestones

Featured News & Press Releases

Oct 12, 2021: Flynpovi: Withdrawal of the marketing authorisation application

Sep 29, 2021: Recursion is granted orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis

Jul 23, 2021: Cancer Prevention Pharmaceuticals has requested a re-examination of EMA’s June 2021 opinion on Flynpovi

Jun 25, 2021: CHMP adopted a negative opinion on the marketing authorisation application for Flynpovi

Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis

Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis

Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis

Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19

Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx

Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis

Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA

Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference

May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis

Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis

Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Familial Adenomatous Polyposis, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Familial Adenomatous Polyposis – Pipeline by ADT Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Cancer Prevention Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Cellix Bio Pvt Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by DNAlite Therapeutics Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Eloxx Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Emtora Biosciences, 2022

Familial Adenomatous Polyposis – Pipeline by FunPep Co Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by Johnson & Johnson, 2022

Familial Adenomatous Polyposis – Pipeline by KD Pharma Group SA, 2022

Familial Adenomatous Polyposis – Pipeline by Recursion Pharmaceuticals Inc, 2022

Familial Adenomatous Polyposis – Pipeline by SanaRx Biotherapeutics Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Stemsynergy Therapeutics Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022

Familial Adenomatous Polyposis – Pipeline by TherapyX Inc, 2022

Familial Adenomatous Polyposis – Pipeline by Thetis Pharmaceuticals LLC, 2022

Familial Adenomatous Polyposis – Dormant Projects, 2022

Familial Adenomatous Polyposis – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Familial Adenomatous Polyposis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.